drugset / Trial / NCT02840136

LC-MS/MS Based Method Development for the Monitoring of Antibiotic Concentrations in Sputum of Cystic Fibrosis Patients

NCT02840136

NaSingle-groupOpen-labelBasic science

Summary

In this trial, various factors that may influence the antibiotic concentrations measured in the sputum of cystic fibrosis patients are studied. A first factor is aerosol use. As cystic fibrosis patients often use aerosols, such as hypertonic saline, dilution of the antibiotics in sputum can be expected. The extent of this dilution is unknown and will be determined by comparing sputum samples collected before and after the use of an aerosol. A second factor is the homogeneity of the antibiotics within one sputum sample. Multiple aliquots of the same sputum sample will be compared. A third factor is the variability between several sputum samples collected during a drainage session. The antibiotic concentrations in 3 separate sputum samples will be compared. The final goal is to standardise the sputum sample collection and processing of the samples to ensure a accurate concentration measurements in sputum.

Timeline

Start
2016-02
Primary completion
2017-09-01
Completion
2017-09-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Ceftazidime Small molecule Intravenous
Subject Meropenem Small molecule Intravenous
Subject Piperacillin Small molecule Intravenous
Background Tazobactam Small molecule Intravenous

Indications